Evidence map›Paper›PMID 35388358›Full record

ArticleJournal of hepatocellular carcinoma2022

Safety and Efficacy of Transarterial Chemoembolization and Immune Checkpoint Inhibition with Camrelizumab for Treatment of Unresectable Hepatocellular Carcinoma.

Jin-Xing Zhang, Pei Chen, Sheng Liu, Qing-Quan Zu, Hai-Bin Shi, Chun-Gao Zhou

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hepatocellular carcinoma, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Conversion therapy using transarterial chemoembolization plus tislelizumab for unresectable hepatocellular carcinoma: effects on tumor necrosis and anti-tumor immune response.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Observational
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Jin-Xing Zhang *Department of Interventional Radiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, 210029, People's Republic of China.
Pei Chen *Department of Basic Medicine, Jiangsu College of Nursing, Huai'an, 223005, People's Republic of China.ORCID 0000-0002-5763-7390
Sheng LiuDepartment of Interventional Radiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, 210029, People's Republic of China.
Qing-Quan ZuDepartment of Interventional Radiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, 210029, People's Republic of China.
Hai-Bin ShiDepartment of Interventional Radiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, 210029, People's Republic of China.
Chun-Gao ZhouDepartment of Interventional Radiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, 210029, People's Republic of China.
Nanjing Medical University · CNJiangsu Vocational College of Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The clinical outcomes of hepatocellular carcinoma (HCC) patients who receive transarterial chemoembolization (TACE) and immunotherapy are not well characterized. The present study evaluates the safety and efficacy of TACE in combination with immune checkpoint inhibitor treatment for unresectable HCC. Methods: A retrospective analysis of 34 HCC patients who received TACE and treatment with the immune checkpoint inhibitor (ICI), Camrelizumab, between July 2019 and May 2021, was performed. This included 21 patients who developed progressive disease and eight who remained stable after several sessions of TACE, along with five patients who were initially diagnosed with advanced HCC. Adverse events (AEs), objective response rate (ORR) according to modified response evaluation criteria in solid tumors, progression-free survival (PFS), and overall survival (OS) were evaluated. Results: The median follow-up from ICI initiation was 10.6 months (range: 2.4-25.0 months). Grade I/II and grade III/IV AEs from ICI treatment occurred in 20 (58.8%) and 2 patients (5.9%), respectively. Two to three months after ICI therapy, the ORR was 35.3% (12/34) and the median PFS and OS was 6.1 months (range: 1.1-19.3 months) and 13.3 months (range: 2.4-25.0 months), respectively. Conclusion: TACE in combination with ICI could be a promising treatment approach for unresectable HCC patients.

Indexed as

efficacyhepatocellular carcinomaimmune checkpoint inhibitionsafetytransarterial chemoembolization

Identifiers

PMID35388358
PMCPMC8979422
OpenAlexW4220734483

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.